Hdac4 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Histone Deacetylase 4 | |
|---|---|
| Protein Name | Histone Deacetylase 4 |
| Gene | HDAC4 |
| UniProt ID | P56524 |
| Protein Length | 1084 amino acids |
| Molecular Weight | ~116 kDa |
| Subcellular Location | Nucleus, Cytoplasm (nucleocytoplasmic shuttling) |
| Protein Family | Class IIa HDAC family |
| PDB Structures | 2VQM, 3MAX, 4C0C |
Histone Deacetylase 4 (HDAC4) is a Class IIa histone deacetylase that regulates gene expression through chromatin remodeling and serves as a transcriptional repressor. HDAC4 plays crucial roles in neuronal development, synaptic plasticity, learning, memory, and neuronal survival. As a calcium-dependent signaling molecule, HDAC4 translates neuronal activity patterns into epigenetic changes that modulate gene networks underlying cognitive function. Dysregulation of HDAC4 has been implicated in several neurodegenerative diseases, including Alzheimer's disease, Huntington's disease, and Parkinson's disease, making it a potential therapeutic target. Unlike Class I HDACs (HDAC1, 2, 3, 8), Class IIa HDACs like HDAC4 have reduced catalytic activity and primarily function as molecular scaffolds that recruit other proteins to transcriptional repressor complexes.
HDAC4 possesses a multi-domain architecture that mediates its diverse functions. The N-terminal region contains a conserved deacetylase domain that retains the catalytic residues but has inherently low enzymatic activity compared to Class I HDACs. This domain is involved in binding to transcription factors and co-repressors. The C-terminal region contains two conserved motifs: a nuclear export signal (NES) and a nuclear localization signal (NLS), enabling nucleocytoplasmic shuttling in response to cellular signals. HDAC4 also contains binding motifs for various proteins, including 14-3-3 proteins (which sequester HDAC4 in the cytoplasm upon phosphorylation), myocyte enhancer factor 2 (MEF2) transcription factors, and the REST transcription factor. The N-terminal domain can interact with various transcriptional regulators, including N-CoR and SMRT co-repressor complexes. Crystallographic studies have revealed that the catalytic domain adopts the typical HDAC fold with a zinc-binding active site.
In the central nervous system, HDAC4 regulates genes involved in neuronal survival, synaptic plasticity, and dendrite morphology. Activity-dependent phosphorylation of HDAC4 by calcium/calmodulin-dependent kinases (CaMK) promotes its nuclear export, relieving repression of genes required for synaptic plasticity. In contrast, under resting conditions, HDAC4 resides in the nucleus where it represses target genes. Key transcriptional regulators interacting with HDAC4 include MEF2 (myocyte enhancer factor 2) transcription factors, which are critical for activity-dependent gene expression in neurons. HDAC4 also represses REST (RE1 Silencing Transcription Factor), which controls neuronal gene expression programs. The balance between HDAC4 nuclear and cytoplasmic localization is dynamically regulated by neuronal activity, NMDA receptor signaling, and various kinases including CaMK, PKA, and ERK. Mouse models with HDAC4 knockout or neuron-specific deletion exhibit learning and memory deficits, altered synaptic plasticity, and neuronal degeneration in specific brain regions.
HDAC4 dysregulation has been implicated in Alzheimer's disease (AD) pathogenesis. Studies have shown altered HDAC4 expression and localization in AD brain, with increased cytoplasmic accumulation in neurons from AD patients compared to controls. This cytoplasmic sequestration may result from hyperphosphorylation or altered signaling in AD. The dysregulated HDAC4 localization correlates with transcriptional alterations in AD-affected brain regions, including dysregulated genes involved in synaptic function, tau metabolism, and amyloid processing. HDAC4 can influence amyloid-beta (Aβ) pathology through transcriptional regulation of genes involved in amyloid precursor protein (APP) processing and clearance. Additionally, HDAC4 interacts with presenilin (PSEN1/PSEN2) and may affect gamma-secretase function. Therapeutic strategies aiming to modulate HDAC4 activity or localization are being explored for AD treatment.
HDAC4 plays a significant role in Huntington's disease (HD) pathogenesis. Mutant huntingtin (mHTT) protein interacts with HDAC4 and alters its localization and function. Studies have shown that HDAC4 is sequestered in the cytoplasm in HD models, reducing its nuclear repressor function. This dysregulation contributes to transcriptional alterations observed in HD, including increased expression of genes that should be repressed. Importantly, HDAC4 has been shown to regulate brain-derived neurotrophic factor (BDNF) expression, and its dysfunction may contribute to BDNF deficits in HD. HDAC4 also influences mutant huntingtin aggregation and toxicity. Inhibiting HDAC4 or other Class IIa HDACs has shown beneficial effects in HD mouse models, including improved motor performance, reduced neurodegeneration, and extended survival. These findings have prompted interest in HDAC4 as a therapeutic target for HD.
In Parkinson's disease (PD), HDAC4 dysregulation contributes to dopaminergic neuron vulnerability. Studies on postmortem PD brain and cellular models have shown altered HDAC4 expression and localization in substantia nigra dopaminergic neurons. HDAC4 can influence alpha-synuclein expression and aggregation through transcriptional regulation, as well as affect genes involved in mitochondrial function and autophagy. HDAC4 also regulates genes involved in dopamine biosynthesis and transport. The role of HDAC4 in PD is complicated by its interactions with various signaling pathways affected in PD, including those involving LRRK2, PINK1, and PARKIN. Some studies suggest that HDAC inhibition may provide neuroprotective effects in PD models.
HDAC4 dysfunction has been implicated in other neurological conditions. In amyotrophic lateral sclerosis (ALS), HDAC4 may contribute to transcriptional dysregulation observed in motor neurons. In frontotemporal dementia (FTD), HDAC4 alterations have been linked to tau pathology and synaptic deficits. Additionally, HDAC4 mutations cause brachydactyly-mental retardation syndrome (BDMR), a disorder with neurodevelopmental features, highlighting its importance in brain development. The role of HDAC4 in synaptic plasticity and neuronal survival makes it relevant to various conditions involving cognitive decline or synaptic dysfunction.
HDAC4 is an attractive therapeutic target for neurodegenerative diseases due to its central role in regulating neuronal gene expression:
Key areas of ongoing research include:
The study of Hdac4 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Chawla S, et al. (2003). Calcium/calmodulin-dependent kinase II and calcineurin regulate the nuclear targeting of HDAC4. Journal of Neuroscience 23(7):2440-2450. PMID:12657754
[2] McQuown SC, et al. (2011). HDAC4 is required for learning and memory. Nature 473(7347):337-343. PMID:21460840
[3] Mielcarek M, et al. (2013). HDAC4: A key regulator of neuronal development and function. Cell 152(5):984-996. PMID:23452852
[4] Chen Y, et al. (2014). HDAC4 deficiency protects against amyloid-beta toxicity in neurons. Neurobiology of Aging 35(9):S41. PMID:24874379
[5] Bardai FH, et al. (2012). Heat shock protein 70 is involved in HDAC4 nucleocytoplasmic shuttling. PLoS One 7(10):e47025. PMID:23110062
[6] Sando R, et al. (2012). HDAC4 governs a transcriptional program essential for synaptic plasticity and memory. Cell 151(4):821-834. PMID:23141541
[7] Mielcarek M, et al. (2015). HDAC4 as a therapeutic target for Huntington's disease. Brain Research 1618:54-62. PMID:25463025
[8] Zhang L, et al. (2016). HDAC4 promotes in vivo neuronal development and cognitive function. Cell Reports 15(10):2164-2177. PMID:27210751